Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Intarcia Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its new drug ...
Intarcia Therapeutics Inc. today provided an update on the company's progress in 2018 and trajectory for advancement in 2019. In 2018, the company...
Intarcia Therapeutics Inc. today announced the appointment of Thane Wettig to the newly created role of Chief Marketing Officer (CMO) and Metabolic...
Intarcia Therapeutics, Inc., a privately held biopharmaceutical company committed to developing innovative therapies to enhance treatment and...
Intarcia Therapeutics, Inc. today announced the appointment of four new members to its board of directors. Dr. Patrick Conway, Jim Rosenthal, Dr. Jay ...
Intarcia Therapeutics, Inc. announced top-line results from FREEDOM-3S which assessed the tolerability and optimal dosing regimen of two different...
Intarcia Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for active review its New Drug Application...
Intarcia Therapeutics, Inc. and the California Institute for Biomedical Research (Calibr) today announced a strategic research collaboration focused...
Intarcia Therapeutics, Inc., today announced that Chairman, President and CEO Kurt Graves will present a Company overview at the J.P. Morgan...
Intarcia Therapeutics, Inc. announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ITCA 650 for ...
Intarcia Therapeutics, Inc. today announced the first closing of a major equity financing that puts the company in a strong strategic and financial...
Intarcia Therapeutics, Inc. today presented positive results from its FREEDOM-2 clinical trial with its late-stage investigational candidate ITCA...
Intarcia Therapeutics, Inc. today announced a troubling and noteworthy analysis of NHANES published data underscoring an urgent need for innovative...
Intarcia Therapeutics, Inc. introduced today the Medici Drug Delivery SystemTM, its innovative proprietary subcutaneous delivery system, comprised of ...
Intarcia Therapeutics, Inc., and Numab AG, today announced the achievement of several key milestones in the development of a multi-specific antibody...
Intarcia Therapeutics, Inc. today announced top-line results from its more than 4,000 patient Cardiovascular Safety Study (FREEDOM-CVO trial),...
Intarcia Therapeutics, Inc., today announced Anthony Hurley has joined the Company in the role of VP, Global Commercial Manufacturing and Operations, ...
Intarcia Therapeutics, Inc. today announced the appointment of John Yee, MD, MPH, into the newly created role of Vice President, Head of Global...
Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview at 9:00 am Pacific Time on...
Intarcia Therapeutics, Inc. today announced the acquisition of Phoundry Pharmaceuticals, Inc., a privately held biotechnology company based in...
Intarcia Therapeutics, Inc. today announced the presentation of results from its first two Phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of...
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative...
Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of...
Intarcia Therapeutics, Inc. today announced that Kurt Graves, Chairman, President and CEO of Intarcia, has been named an EY Entrepreneur Of The Year® ...
Intarcia Therapeutics, Inc. today announced its Company-sponsored presentations at the upcoming 75th Scientific Sessions of the American Diabetes...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.